This article is a correction to:
Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes
Frontiers Editorial OfficeAn Expression of Concern on
Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes
by Wang H-Y, Pei Z, Lee K-C, Nikolov B, Doehner T, Puente J, Friedmann N and Burns LH (2023). Front. Aging 4:1175601. doi: 10.3389/fragi.2023.1175601
With this notice, Frontiers states its awareness of concerns regarding the images for “Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes” published on the 29th of June 2023. An investigation is currently being conducted in accordance with COPE guidelines. This notice will be updated as soon as the investigation is complete.
Citation: Frontiers Editorial Office (2024) Expression of concern: Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes. Front. Aging 5:1483030. doi: 10.3389/fragi.2024.1483030
Received: 19 August 2024; Accepted: 19 August 2024;
Published: 22 August 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org